colossal biosciences

7+ articles

AI chips Biotech Blue Origin Brown-Forman CRISPR

Templum and SoFi Team Up to Bring Private Market Gems to Members!

Templum is partnering with SoFi to offer its members a unique opportunity to invest in Perplexity AI, OpenAI, and Colossal Biosciences through the Cosmos Fund. Running from March 5 to 30, 2026, this exclusive chance is open to qualified investors and represents a push to democratize access to high-demand private market investments. From conversational AI to mind-blowing biotech projects, these companies are sure to draw investor excitement—so get ready!

Mar 6

Templum and SoFi Team Up to Bring Private Market Gems to Members!

Colossal Biosciences Tackles Dire Wolf De-Extinction Query with Wit

In a delightful exchange, Colossal Biosciences addressed an inquiry by an Indian man about the de-extinction of the dire wolf species. The firm, known for its de-extinction efforts, responded with humor, highlighting the scientific curiosity and innovation propelling this fascinating field forward.

Apr 8

Colossal Biosciences Tackles Dire Wolf De-Extinction Query with Wit

Colossal Biosciences Responds to Exciting De-extinction Query from India

In an intriguing turn of events, Colossal Biosciences has addressed a query from an Indian enthusiast about the potential de-extinction of the legendary dire wolf. Known for their groundbreaking work in de-extincting species, Colossal Biosciences is the talk of the town with this latest interaction. What could this mean for the future of de-extinction?

Apr 8

Colossal Biosciences Responds to Exciting De-extinction Query from India

Tech Titans Shake the World with Bold Moves and Controversies

From major layoffs at Meta to Nvidia's pushback against U.S. chip restrictions, tech leaders are making bold moves and facing controversies. Meanwhile, TSMC reports record AI chip profits, Blue Origin's rocket launch marks a milestone, and Colossal Biosciences raises ethical debates with massive funding. Discover how these events are shaping the future of technology.

Jan 17

Tech Titans Shake the World with Bold Moves and Controversies

Colossal Biosciences Achieves Decacorn Status with $200M Series C Funding

Colossal Biosciences, the trailblazer in de-extinction technology, has secured an impressive $200 million in Series C funding, propelling its valuation to decacorn status at $10.2 billion. Founded in 2021, the company leverages CRISPR gene editing to revive extinct species like the woolly mammoth and dodo. With total funding reaching $435 million, Colossal aims to further advance its genetic engineering technologies, with promising applications in conservation, healthcare, and evolutionary biology.

Jan 17

Colossal Biosciences Achieves Decacorn Status with $200M Series C Funding

Quiz Craze: Financial Insights from Lawsuits to Layoffs!

Get in the loop with Sherwood Media’s interactive quiz covering the hottest financial stories—from Colossal Biosciences' epic $10B de-extinction ambitions to Wells Fargo's legal troubles and Brown-Forman's strategic layoffs. Can you ace this test of economic savvy?

Jan 17

Quiz Craze: Financial Insights from Lawsuits to Layoffs!

Colossal Biosciences Bags $200M to Revive Woolly Mammoths at a Digiextinctive $10.2B Valuation!

Colossal Biosciences has raised a staggering $200M in Series C funding to resurrect the woolly mammoth using cutting-edge de-extinction technology, edging its valuation to $10.2B. By blending genome mapping and CRISPR gene-editing, the company aims to restore extinct species while spinning off transformative technologies. What does this mean for the future of biodiversity and biotech?

Jan 17

Colossal Biosciences Bags $200M to Revive Woolly Mammoths at a Digiextinctive $10.2B Valuation!